<DOC>
	<DOCNO>NCT00113919</DOCNO>
	<brief_summary>The purpose study find patient high risk disease age kidney status treat safely drug call Busulfex® follow autologous transplant compare treatment standard drug call melphalan , show quite difficult tolerate patient poor kidney function patient age 65 give high dos .</brief_summary>
	<brief_title>UARK 2003-25 : A Study Intravenous ( IV ) Busulfan ( Busulfex® ) Multiple Myeloma Patients</brief_title>
	<detailed_description>This trial determine maximal dose Busulfex® give two , three , four day period acceptable toxicity myeloma patient , either &gt; = 65 year age renal insufficiency , define creatinine &gt; 3g/dL creatinine clearance &lt; 30 ml/min .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients must symptomatic multiple myeloma require treatment Patients must approve single tandem autologous transplant Patients must &gt; = 65 year age diagnose renal insufficiency , define creatinine &gt; 3 mg/dl creatinine clearance &lt; 30 ml/minute Patients must history chronic obstructive chronic restrictive pulmonary disease . Patients must adequate pulmonary function study &gt; 50 % predict mechanical aspect ( FEV1 , FVC , etc ) diffusion capacity ( DLCO ) &gt; 50 % predict , Patients must ECHO MUGA perform within 60 day prior registration , LVEF &gt; 40 % . Bilirubin , SGOT , SGPT must less 1.5 time upper limit normal Patients must evaluable myeloma marker response : *Serum M protein &gt; 1g/dl urine M protein &gt; 1g/24 hour and/or ; *Bone marrow plasmacytosis &gt; 20 % plasma cell and/or ; *Extramedullary plasmacytosis ; *MRI/PET scan focal lesion due myeloma . Patients must able receive full dos DTPACE , opinion treat investigator , exception cisplatin . Patients must performance status 02 base SWOG criterion unless patient 's status due active myeloma All patient must inform investigational nature study sign IRBapproved inform consent accordance institutional federal guideline . Serum transaminases &gt; 1.5 x ULN direct bilirubin &gt; 1.5 mg/dl HIV positive active Hepatitis B Hepatitis C infection ; ( serology positive quantitative PCR do ) . Patients prior malignancy life expectancy likely determine prior malignancy myeloma . Patients must currently receive therapy prior malignancy . Pregnant nursing woman . Women childbearing potential must negative pregnancy test document within one week registration . Women/men reproductive potential may participate unless agree use effective contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Myeloma , MM</keyword>
</DOC>